Lilly Rips Page From Big Pharma Playbook: Reorganize, Cut Costs
This article was originally published in The Pink Sheet Daily
Executive Summary
Cost reduction plan is aimed at saving $1 billion by the end of 2010 ahead of the patent expiration of Zyprexa.
You may also be interested in...
Lilly Stands By Experimental Diabetes Drug, Despite Questions About Data
Despite early evidence that one of its experimental diabetes drugs may cause higher heart and blood pressure rates, Eli Lilly remains adamant that development should continue
Lilly Stands By Experimental Diabetes Drug, Despite Questions About Data
Despite early evidence that one of its experimental diabetes drugs may cause higher heart and blood pressure rates, Eli Lilly remains adamant that development should continue
Lilly Stands By Experimental Diabetes Drug, Despite Questions About Data
Recent data showing faster heart and blood pressure rates lead some analysts to question the drug maker's strategy for its diabetes drug.